Component Pertussis based Infants Vaccine C DTcP 

Pertussis, also known as whooping cough, is an acute respiratory tract infection caused by Bordetella pertussis. It is usually manifested as paroxysmal spasmodic cough accompanied by high-pitched whoop sound when infected individuals attempt to inhale. It can last for up to three months and thus is also called the 100 days cough in some countries.

The wide use of pertussis vaccines has substantially reduced its incidence and death rate. However, according to World Health Organization (WHO), the disease annually infects 48.5 million people worldwide, resulting in nearly 2.94 million deaths. In recent years, pertussis incidence has been rising significantly, especially in adolescents and adults, who have become a high-risk population. Adult carriers of B. pertussis are also an important source of infection for infants/toddlers. Therefore, pertussis reemergence has attracted lots of attention from health care professionals. 

In China, a Diphtheria, Tetanus, acellular Pertussis Vaccine (DTaP) has been introduced into a routine immunization schedule for newborns, but the composition of this vaccine is not well defined. Moreover, the current DTaP is not formulated for adults.

Among all pertussis vaccines, component pertussis vaccine causes the least adverse effects. CanSino has been making efforts to develop a type of Diphtheria-Tetanus toxoids-component Pertussis vaccine (DTcP) to better protect infants in addition to launching a diphtheria-tetanus toxoids-component pertussis vaccine for Adults (dtcp). In this way, CanSino will be able to satisfy the demand for adult and infant pertussis vaccines in emerging markets.